pediatric review international journal of pediatric research

Indexing & Abstracting

Pediatrics Review: International Journal of Pediatrics Research is constantly upgrading its indexing and abstracting in various agencies. Regular efforts are made to archive published manuscripts in various archiving platforms which are authenticate.

1. Index Copernicus

2. Crossref

3. PKP: The PKP Index is a database of articles, books, and conference proceedings using PKP's free, open source Open Journal Systems, Open Monograph Press, and Open Conference Systems software applications.

Metadata Harvesting

1. Open Archives Initiative (OAI-PMH) (To verify, Click Here )

• Study of C-reactive protein in healthy neonates 1653
• Effect of dengue fever on the total leucocyte count and neutrophil count in children in early febrile period 1020
• Effect of Gayatrimantra chanting on cognitive functions in school children 993
• Astudy of knowledge about immunization amongst mothers of children below 5 years of age 967
• Effect of L- Carnosine, DHA and vitamin D3 on children with down’s syndrome- a pilot study on Indian population 801

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• Springer Nature - PMC COVID-19 Collection

The state and future of pediatric research—an introductory overview

Esther m. speer.

1 Department of Pediatrics, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY USA

Lois K. Lee

2 Department of Pediatrics, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA

Florence T. Bourgeois

3 Computational Health Informatics Program, Boston Children’s Hospital, Boston, MA USA

Daniel Gitterman

4 Public Policy, University of North Caroline, Chapel Hill, NC USA

William W. Hay, Jr.

5 University of Colorado, Denver, CO USA

Jonathan M. Davis

6 Department of Pediatrics and the Tufts Clinical and Translational Science Institute, Tufts Medical Center, Boston, MA USA

Joyce R. Javier

7 Department of Pediatrics, Children’s Hospital Los Angeles, Keck School of Medicine of the University of Southern California, Los Angeles, CA USA

Associated Data

All data pertaining to this report are contained in this special article.

• This is an introduction to an article series devoted to the current state and future of pediatric research.
• The role of public–private partnerships, influencing factors, challenges, and recent trends in pediatric research are described, with emphasis on funding, drug and device development, physician-scientist training, and diversity.
• Potential solutions and advocacy opportunities are discussed.

Introduction

Children have unique and rapidly changing physical, psychosocial, and developmental needs. Addressing early-life diseases and adverse childhood experiences has lifelong benefits for individuals, families and communities. This may also limit or even prevent many chronic adult-onset diseases that originate in early life. However, most pediatric researchers face financial, regulatory, institutional, ethical, and career challenges (Table  1 ), placing pediatric research at a distinct disadvantage compared to adult investigations (Fig.  1 ).

Current challenges and potential solutions to promote pediatric research.

The most important factors are highlighted as bold text.

I-ACT for Children Institute for Advanced Clinical Trials in Children, IMG international medical graduate, NIH National Institutes of Health, RCT randomized controlled trial, SHIP-MD System of Hospitals for Innovation in Pediatrics-Medical Devices.

Factors influencing pediatric research, pediatric health and disease, as well as adult health and disease are illustrated with arrows.

Federal research funding

Pediatric research funding from the National Institutes of Health (NIH), the largest public funding agency worldwide, has been historically low compared to funding for adult diseases. 1 , 2 Although pediatric NIH spending has increased over time, the purchasing power of their pediatric and perinatal research portfolio declined by 15.9% and 12.4%, respectively from 2004 to 2015. 2 Fortunately, pediatric funding has recently significantly increased due to fiscal and legislative responsiveness requiring NIH to report pediatric research spending annually. 3 Nonetheless, high inflation and the COVID-19 pandemic may place future pediatric research funding at risk. Furthermore, priorities for federal pediatric research support may need to be adjusted to account for rapidly changing healthcare needs 4 and pediatric disease burden. 5

Drug and device development

Pediatric drug and device development continues to lag behind programs addressing adult conditions. Industry-sponsored trials involving children remain limited due to expected lower profitability. Heightened regulatory, ethical, and safety standards for clinical trials involving pregnant women and children, and issues with obtaining parental informed consent and child assent highlight the considerable challenges. Most pediatric diseases are considered rare, which often results in trial prolongation and inadequate enrollment. 6 Pre-clinical models for many childhood diseases are lacking and designing pediatric studies requires multiple stakeholders; outcome measures are not uniformly standardized 7 and assessing the impact of interventions on neurodevelopmental outcomes can require years of follow-up. Many pediatric clinical research sites do not enroll a single patient, often due to limitations with a highly trained workforce. Consequently, most drugs and devices used in children are not approved by the US Food and Drug Administration (FDA) and approximately two-thirds of FDA-approved drugs and biologics with indications relevant to children are marketed for longer than 5 years without adequate pediatric safety and efficacy labeling. 8 Likewise, most FDA approvals of high-risk pediatric devices are based on adult trials, with few children exposed to these devices before market availability. 9

To address these shortcomings, several legislative and regulatory changes have been enacted. The Best Pharmaceuticals for Children Act (2002) incentivizes pharmaceutical companies to test drugs in children by giving them an additional 6 months of market exclusivity. The Pediatric Research Equity Act (2003) and the NIH Inclusion Across the Lifespan Policy (2017) mandate the inclusion of participants of all ages in human subject research. Several public–private partnerships and other national/international research collaborations have recently emerged, designed to streamline pediatric clinical trial processes and drug and device development. These include the International Neonatal Consortium (oversight by the Critical Path Institute), a global collaboration that focuses on novel regulatory pathways for evaluating the safety and effectiveness of neonatal therapies, 10 the FDA-sponsored System of Hospitals for Innovation in Pediatrics-Medical Devices initiative to accelerate pediatric device development, and the Institute for Advanced Clinical Trials for Children to facilitate multicenter studies for pediatric drug development.

Perspective of academic institutions

Academic medical institutions face increasing financial constraints due to: (1) external competition, (2) expanded regulatory requirements, (3) limited funding, (4) rising provider costs, (5) the need to educate junior physician-scientists, (6) increased costs of conducting high-quality research, and (7) providing medical care to a diverse population with limited reimbursement. 11 , 12 Pediatric departments are especially impacted by financial burdens due to increasing proportions of Medicaid recipients, heightened consumer expectations and regulatory requirements, limited NIH and industry funding, and escalating medical costs. 11 These limitations can reduce support for pediatric research infrastructure and training. New organizational and aligned strategic funding models incorporating departmental research support may help to overcome these challenges. 11 Improved federal funding is also essential to train the pediatric physician workforce, as requested by the American Hospital Association and 25 other healthcare organizations. 13

Physician-scientist training

Pediatric NIH funding is increasingly concentrated in relatively few research-intensive institutions, challenging diversity in research and further impacting the physician-scientist pipeline. Over a 5-year period, 15 institutions received 63% of all pediatric R01-equivalent NIH awards. 14 The majority of R01-funded pediatric physician-scientists were male (63.6%), full professors (58%), and held senior leadership positions (24%). Only 15% of pediatric R01-awards were granted to non-professor physician-scientists. 14 Furthermore, the success rate for NICHD career development awards has declined since 2010. 14 The limited support for junior pediatric physician-scientists, compounded by individual career choices and competing clinical responsibilities, has created a declining and aging pediatric research workforce. This may limit future discoveries and innovative therapies for children. 15 Several recent initiatives are now addressing this gap. One example is the National Pediatric Physician-Scientist Collaborative Workgroup, a collaborative of physician-scientists, graduate medical education leaders, department chairs, and trainees from 19 pediatric programs across the US which aims to strengthen the pediatric physician-scientist pipeline. 16 Mentorship at the institutional, regional and national level fosters networking opportunities and support for aspiring pediatric researchers. Another important program includes the NIH Loan Repayment Program to recruit and retain highly qualified health professionals into research careers. Offering early-career formal research education during medical school and physician training can lead to greater future academic productivity and funding success, thus strengthening the physician-scientist workforce. 17

Gender and racial/ethnic diversity

Despite comparable enrollment in medical schools, women account for only 18% of hospital chief executive officers and 16% of all deans and department chairs in the US. 18 Women remain in the minority as senior authors (10%) and editors-in-chief (7%) at high-ranking medical journals. 18 They also comprise less than one-third of NIH-awardees, even though they are as successful as men in obtaining first-time grants. 19 Factors contributing to these disparities include implicit gender bias and institutional policies disadvantaging women. Early-stage investigator or career development grants sponsored by NIH or other funders are limited to scientists who finished their training within 10 years, which disproportionately disadvantages women. 20 Race and ethnicity also impact career trajectories of physician researchers. 21 The Coalition for Pediatric Medical Research is now addressing the need to train the next generation of diverse pediatric researchers. Furthermore, innovative solutions to integrate international medical graduates into the research workforce in addition to increased funding for US-trained physicians represent one strategy to address the current physician-scientist shortage. 22 Finally, clinical studies must be designed to improve the participation of underrepresented populations, 23 to ensure that drugs and devices are studied in target populations who will benefit most from such interventions. This can be accomplished through community-based participatory research including parental engagement for pediatric trials. 24

Dissemination, data sharing and reuse

Timely dissemination of trial results through peer-reviewed publications, registries, and data depositories are imperative to facilitate evidence-based care and decision-making. The FDA Amendments Act (2007) and the NIH require that trials are prospectively registered in CinicalTrials.gov and that summary results of FDA-regulated or NIH-funded interventional trials are made available within 12 months of primary study completion. However, only 39% of registered pediatric trials reported results in peer-reviewed publications and 23.5% in the ClinicalTrials.gov registry by 3 years. 25 Notably, 11% of trials were discontinued early, with recruitment failure as the most common cause. 25 The NIH Policy on Data Sharing (2003) requires a data-sharing plan in all grant applications and the International Committee of Medical Journal Editors (LCMJE) requires a data-sharing statement. However, less than a third of LCMJE-affiliated journals have implemented a data-sharing policy and only a few published trials provided individual patient data in repositories. 26 , 27 Improved monitoring and incentives for data sharing and timely dissemination of trial results may overcome these problems.

Implications for patient outcomes

High-level evidence from clinical studies remains limited for many pediatric diseases and interventions. Most pediatric studies registered in ClinicalTrials.gov are small-scale, single-center, and not funded by industry or the federal government, which translates into fewer drugs being studied over time. 28 Published pediatric studies involve significantly fewer randomized controlled trials (RCTs), systematic reviews, and therapeutic trials compared to adults. 29 This has significant implications for child health with preterm birth and neonatal infections remaining the leading causes of mortality during the first month of life, accounting for approximately half of the 2.4 million neonatal deaths annually worldwide; there has been limited progress over the past 2 decades due in part to a lack of quality RCTs in this area. 30 – 32

There remains an urgent need to communicate 33 and advocate healthcare institutions, elected officials, funders, and the public that promoting research focused on fetal and early life has lifelong benefits for children, adults, and society. 34 The COVID-19 pandemic has proven that advances in pediatric and adult research can be achieved expediently, especially when governments promote the development of public–private partnerships and global collaboration. Broad support for NIH-sponsored pediatric and perinatal research, enforcement of existing NIH and FDA mandates related to clinical trial reporting, data sharing and reuse, inclusion of children in clinical research, collaborative science, and advocacy hold great promise to advance research and benefit children and future adults.

Author contributions

E.M.S. wrote the initial draft of the manuscript. All authors substantially contributed to the conception and content of the article, critically revised the manuscript for important intellectual content, and approved the final version for publication.

Data availability

Competing interests.

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals
• Explore content
• About the journal
• Publish with us
• Sign up for alerts

Journal Information

On this page:  Aims and scope of journal  |  Journal metrics | Abstracted/indexed in | ISSN and eISSN | Benefits of publishing with PR |  Newsfeeds

Aims and scope of journal

Pediatric Research publishes original translational research papers, invited reviews, and commentaries on the etiologies and treatment of diseases of children and disorders of development, extending from basic science to epidemiology and quality improvement.

Topic Areas Adolescent Medicine, Allergy, Anesthesia, Behavior, Bioethics/Palliative Care, Cardiology, Cardiometabolic Disorders, Clinical Research/Methodology, Controversies, Critical Care, Development, Developmental Biology, Diversity, Equity and Inclusion, Emergency Medicine, Endocrinology, Environmental Health, Epidemiology, Fetus & Pregnancy, Gastroenterology, General Pediatrics, Genetics & Epigenetics, Global Health, Health Equity, Health Services Research, Hematology, Hyperbilirubinemia, Immunology, Infectious Disease, Kawasaki Disease, Microbiome, Neonatal Neurology, Neonatology, Nephrology, Neuroimaging, Neurology, Nutrition, Obesity, Oncology, Patient Safety, Pharmacology, Precision Medicine, Public Health, Pulmonology, Quality Improvement, Regenerative Biology, Rheumatology, Stem Cells, Substance Abuse, Transplantation, Toxicology.

Pediatric Research 's mission statement

Optimize children's health by publishing and communicating peer reviewed science and to foster the development of future pediatric researchers.

Journal Metrics

Article metrics such as number of downloads, citations and online attention are available from each article page, and provide an overview of the attention received by a paper.

2022 Citation Metrics

2-year Impact Factor*: 3.6 5-year Impact Factor*: 3.7 Immediacy index*: 0.6 Eigenfactor® score*: 0.01624 Article influence score*: 1.1 Journal Citation Indicator*: 1.22 SNIP**: 1.273 SJR***: 1.040

*2022 Journal Citation Reports® Science Edition (Clarivate Analytics, 2023) **Source-normalized Impact per Paper (Scopus) ***SCImago Journal Rank (Scopus)

2023 Usage Metrics

Downloads: 4,039,474 Altmetric mentions: 6,427

Abstracted/indexed in

Crossref PubMed British Library CAS Copyright Clearance Center EBSCO ExLibris GNM Healthcare Clarivate Analytics (Web of Science) PORTICO Scopus ProQuest Yewno UNSILO

ISSN and eISSN

The international standard serial number (ISSN) for Pediatric Research is 0031-3998 and the electronic international standard serial number (eISSN) is 1530-0447.   

Benefits of publishing with  PR

• We are the official publication of the American Pediatric Society, the European Society for Paediatric Research, and the Society for Pediatric Research.
• We publish original translational research papers, invited reviews, and commentaries on the etiologies and treatment of diseases of children and disorders of development, extending from basic science to epidemiology and quality improvement.
• We have an established reputation built up over 50 years with wide visibility on nature.com and in print.

Publishing with  PR  and Springer Nature provides an author with a wide range of benefits:

License to Publish

The International Pediatric Research Foundation does not require authors of original research papers to assign copyright of their published contributions. Authors grant the International Pediatric Research Foundation an exclusive license to publish, in return for which they can re-use their papers in their future printed work.

In addition, authors are encouraged to archive their version of the manuscript in their institution's repositories (as well as on their personal web sites), six months after the original publication. Authors should cite the publication reference and doi number on any deposited version, and provide a link from it to the published article on the Springer Nature website. This policy complements the policies of the US National Institutes of Health, the Wellcome Trust and other research funding bodies around the world. Springer Nature recognizes the efforts of funding bodies to increase access of the research they fund, and strongly encourages authors to participate in such efforts.

Daily publication online

New articles in  PR , as in all Springer Nature journals, are published daily online ahead of the archival print issue, ensuring the research is made publicly available and can be cited as soon as possible after acceptance for publication. The online publication is a preliminary, unedited version, available on average less than a week after receipt by production.

Supplementary online material

Authors are invited to submit additional supporting material such as data sets or video for publication in the online version of the journal. Online supplementary material makes the most of the Web as a delivery platform and can often give articles greater depth, making them more useful to readers.

Authors who choose to publish in any Springer Nature journal can be assured that its staff's publishing, editorial and production skills are committed to maintaining the highest possible quality and standards.

Exposure - widest possible readership

All Springer Nature journals including  PR , are available online via site licenses to academic, corporate and government institutions and consortia. Journals are available to members of these institutions at the click of a mouse, adding speed and visibility to authors' research papers.

Regular free e-mail alerts

Content published in  PR  has the potential to reach scientists around the world who have signed up for Springer Nature's free table of contents e-alerts, ensuring additional exposure to authors. These e-alerts allow recipients to click through to the full article if they subscribe or work at an institution with a site license, or click through to the article's abstract for other readers.

Focused subject areas on nature.com

From immunology to physics, genetics to materials, subject-specific areas provide a focused environment for readers, providing a monthly updated focus for a particular field.

Abstracting and indexing

PR  is included in the leading abstracting and indexing services including ISI, MEDLINE, EMBASE and BIOSIS. Extensive reference linking to MEDLINE, ISI, Chemport and others via services such as Crossref and DOI numbers provide seamless online linking between articles and databases.

Media coverage

The Springer Nature press office provides information about exceptionally interesting papers published throughout Springer Nature. More than 2,000 journalists and media organizations worldwide subscribe to the press service, ensuring that papers receive maximum exposure in the world's most important media channels including newspapers, magazines, radio and television.

Extending science further - global collaborations

Springer Nature and  PR  support some projects aimed at making current research available to a broader community of scientists and practitioners.

All Springer Nature journals, including  PR , are in WHO's HINARI (Health InterNetwork Access to Research Initiative) program, which provides free access to public institutions in developing countries.

Pediatric Research now provides its latest table of contents as an RSS web  feed. This allows users with an RSS reader to receive automatic updates whenever new content is added to these pages.

Receive Pediatric Research' s current issue table of contents.

Find out more about RSS feeds , how to download an RSS reader and see all the news feeds offered by Springer Nature.

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies